Research programme: anaesthetics - The Medicines Company

Drug Profile

Research programme: anaesthetics - The Medicines Company

Latest Information Update: 10 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Annovation BioPharma
  • Developer The Medicines Company
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaesthesia

Most Recent Events

  • 04 Feb 2015 Annovation BioPharma has been acquired by The Medicines Company
  • 11 Jun 2014 This programme is still in active development in the US
  • 10 Sep 2012 Preclinical trials in Anaesthesia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top